BYFAVO

This brand name is authorized in Estonia, Finland, Croatia, Ireland, Lithuania, Poland, Romania, United Kingdom, United States

Active ingredients

The drug BYFAVO contains one active pharmaceutical ingredient (API):

1 Remimazolam UNII 280XQ6482H - REMIMAZOLAM BESYLATE

Remimazolam is an ultra-short acting benzodiazepine sedative. The effects of remimazolam on the CNS are dependent on the dose administered intravenously and presence or absence of other medicinal products. Remimazolam binds to benzodiazepine sites of gamma amino butyric acid type A [GABAA] receptors with high affinity, while its carboxylic acid metabolite (CNS7054) has approximately 300 times lower affinity for these receptors. Read about Remimazolam

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
BYFAVO Powder for solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC
BYFAVO Powder for solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N05CD14		N Nervous system → N05 Psycholeptics → N05C Hypnotics and sedatives → N05CD Benzodiazepine derivatives
Discover more medicines within N05CD14

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1846076
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 426511
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 398859
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1092326
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100461017
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69478001
Country: US	FDA, National Drug Code	Identifier(s): 71390-011